Cyteir Therapeutics Stock Annual Yield
CYTDelisted Stock | USD 2.76 0.01 0.36% |
Cyteir Therapeutics fundamentals help investors to digest information that contributes to Cyteir Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyteir Stock. The fundamental analysis module provides a way to measure Cyteir Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyteir Therapeutics stock.
Cyteir |
Cyteir Therapeutics Company Annual Yield Analysis
Cyteir Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
CompetitionIn accordance with the recently published financial statements, Cyteir Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
All Next | Launch Module |
Cyteir Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | -0.14 | |||
Current Valuation | (20.89 M) | |||
Shares Outstanding | 36 M | |||
Shares Owned By Insiders | 6.63 % | |||
Shares Owned By Institutions | 76.83 % | |||
Number Of Shares Shorted | 319.73 K | |||
Price To Earning | 0.36 X | |||
Price To Book | 0.87 X | |||
Gross Profit | (16.59 M) | |||
EBITDA | (33.41 M) | |||
Net Income | (33.22 M) | |||
Cash And Equivalents | 166.4 M | |||
Cash Per Share | 4.71 X | |||
Total Debt | 889 K | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 19.95 X | |||
Book Value Per Share | 3.47 X | |||
Cash Flow From Operations | (25.79 M) | |||
Short Ratio | 3.07 X | |||
Earnings Per Share | (0.93) X | |||
Price To Earnings To Growth | (0.03) X | |||
Target Price | 3.0 | |||
Number Of Employees | 46 | |||
Beta | 0.096 | |||
Market Capitalization | 108.71 M | |||
Total Asset | 153.23 M | |||
Retained Earnings | (138.11 M) | |||
Working Capital | 143.89 M | |||
Current Asset | 834.8 M | |||
Current Liabilities | 366.9 M | |||
Net Asset | 153.23 M |
About Cyteir Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyteir Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyteir Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyteir Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |